

FOLLICULAR LYMPHOMA (FL) RESOURCE GUIDE

EDUCATIONAL AND SUPPORT RESOURCES, AND ORGANIZATIONS THAT MAY BE HELPFUL DURING YOUR TREATMENT

Beginning a new FL treatment can be overwhelming, but it's important to know that you're not alone. We've put together a list of some FL educational and support resources, and organizations for people with FL and their caregivers. These resources may provide tips on living a healthy lifestyle, educational disease information, financial support, and someone to talk to.

To learn more, please contact the organization you're interested in for more information.

Information provided within this resource guide is not intended to be a substitute for a healthcare provider's advice. Questions about FL and lifestyle recommendations should be discussed with your doctor.

INDICATIONS

What is TAZVERIK?

TAZVERIK is a prescription medicine used to treat:

- Adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, and who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure TAZVERIK is right for you.
- Adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TAZVERIK? TAZVERIK can cause serious side effects, including:

 Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

(tazemetostat) tablets

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Medication Guide, in the pocket.

LYMPHOMA PATIENT ADVOCACY ORGANIZATIONS

Lymphoma Research Foundation

www.lymphoma.org

The Leukemia & Lymphoma Society

www.LLS.org

Follicular Lymphoma Foundation

www.theflf.org

Your healthcare provider, insurance, or hospital system may also have information about local support groups.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about TAZVERIK? (continued)

Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you:

- Are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.
- Females who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.
- Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.

GENERAL CANCER ADVOCACY ORGANIZATIONS

American Cancer Society

www.cancer.org

Cancer Care

www.cancercare.org

Cancer.Net

www.cancer.net

Family Caregiver Alliance

www.caregiver.org

Cancer Support Community

www.cancersupportcommunity.org

IMPORTANT SAFETY INFORMATION (continued)

Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you:

 Are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Medication Guide, in the pocket.

All organizations identified above are not-for-profit and/or government agencies that are unaffiliated with and operate independent of Ipsen, Inc. ("Ipsen"). Ipsen may provide funding support to 1 or more of the organizations listed.



FINANCIAL SUPPORT

To help facilitate access to TAZVERIK® for patients with a valid prescription, the Ipsen Cares patient support program offerings can help you understand your insurance coverage and identify financial or product support that may be available to you.



If you are interested in learning more, visit **ipsencares.com** or contact Ipsen Cares Patient & Product Support at **1-866-435-5677**, Monday through Friday, 8 AM – 8 PM ET.

IMPORTANT SAFETY INFORMATION (continued)

What should I avoid while taking TAZVERIK?

- Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.
- Avoid taking St. John's wort during treatment with TAZVERIK.

Talk to your healthcare provider before starting any new medications, vitamins, or herbal supplements.

What are the possible side effects of TAZVERIK?

The most common side effects of TAZVERIK in people with follicular lymphoma include:

- Tiredness
- Cold-like symptoms (upper respiratory infection)
- Bone and muscle pain
- Nausea
- Stomach (abdominal) pain

These are not all the possible side effects of TAZVERIK.

Call your doctor for medical advice about side effects. You may report side effects to Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Medication Guide, in the pocket.



